| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/08/2006 | WO2006060711A3 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| 09/08/2006 | WO2006059346A3 An improved process for lactonization to produce highly pure statins |
| 09/08/2006 | WO2006056145A3 Osmotic device containing a venlafaxine salt and a salt having a common ion |
| 09/08/2006 | WO2006055553A3 Novel m3 muscarinic acetylcholine receptor antagonists |
| 09/08/2006 | WO2006055542A3 Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use |
| 09/08/2006 | WO2006053882A3 Benzothiazole formulations and use thereof |
| 09/08/2006 | WO2006051502A3 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 09/08/2006 | WO2006048665A3 Polymorphs of sarsapogenin |
| 09/08/2006 | WO2006044497A3 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease |
| 09/08/2006 | WO2006034414A3 Loxapine analogs and methods of use thereof |
| 09/08/2006 | WO2006032053A3 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds |
| 09/08/2006 | WO2006031901A3 SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF |
| 09/08/2006 | WO2006030324A3 Testosterone stimulant |
| 09/08/2006 | WO2006030306A3 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| 09/08/2006 | WO2006029142A3 Methods and systems for treating asthma and other respiratory diseases |
| 09/08/2006 | WO2006029010A3 Methods of activating nkt cells |
| 09/08/2006 | WO2006026273A3 Method of treating atherosclerosis, dyslipidemias and related conditions |
| 09/08/2006 | WO2006023211A3 Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof |
| 09/08/2006 | WO2006021008A3 Ionophores as cancer chemotherapeutic agents |
| 09/08/2006 | WO2006010152A3 Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones |
| 09/08/2006 | WO2006008091A3 Oxidative degradation products of atorvastatin calcium |
| 09/08/2006 | WO2006007851A3 Capsaicin inhibitors for treating obesity and-related disorders |
| 09/08/2006 | WO2006006080A3 Sodium channel agonist |
| 09/08/2006 | WO2005117907A3 P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions |
| 09/08/2006 | WO2005105103A3 Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| 09/08/2006 | WO2005094374A3 Hydrazide-containing cftr inhibitor compounds and uses thereof |
| 09/08/2006 | WO2005089734A3 Creatine salt enhanced nutritional and therapeutic efficacy and compositions containing same |
| 09/08/2006 | WO2005089372A3 Therapeutic synergy of anti-cancer compounds |
| 09/08/2006 | WO2005086754A3 Dicationic compounds for activity against trichomonas vaginalis |
| 09/08/2006 | WO2005051980A8 Depeptidized inhibitors of hepatitis c virus ns3 protease |
| 09/08/2006 | WO2005035551A3 Inhibitors of proteins that bind phosphorylated molecules |
| 09/08/2006 | WO2005034882A3 Composition and method to treat solid tumors |
| 09/08/2006 | WO2005025517A3 Animal model for protease activity and liver damage |
| 09/08/2006 | WO2004075724A3 Serotonin and catecholamine system segment optimization technology |
| 09/08/2006 | WO2004053106A3 Profiled regulatory sites useful for gene control |
| 09/08/2006 | WO2003062255A3 Sugar modified nucleosides as viral replication inhibitors |
| 09/08/2006 | WO2003028696A8 Compositions for delivery of drug combinations |
| 09/08/2006 | CA2833783A1 Design and synthesis of novel antimicrobials |
| 09/08/2006 | CA2819464A1 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| 09/08/2006 | CA2644686A1 Methods and compositions for increasing the safety and efficacy of albumin-binding drugs |
| 09/08/2006 | CA2644652A1 Combinaion therapy for topical application in the treatment of dry eye syndrome |
| 09/08/2006 | CA2610343A1 Release-control composition |
| 09/08/2006 | CA2603534A1 Design and synthesis of novel antimicrobials |
| 09/08/2006 | CA2601129A1 Crystallisation and purification of glycopyrronium bromide |
| 09/08/2006 | CA2600933A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 09/08/2006 | CA2600891A1 Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
| 09/08/2006 | CA2600890A1 Salts, addition compounds and complex compounds of guanidinoacetic acid |
| 09/08/2006 | CA2600287A1 Use of cinnamoyl compound |
| 09/08/2006 | CA2599992A1 Acridine and quinoline dervatives as sirtuin modulators |
| 09/08/2006 | CA2599989A1 N-phenyl benzamide derivatives as sirtuin modulators |
| 09/08/2006 | CA2599987A1 Fused heterocyclic compounds and their use as sirtuin modulators |
| 09/08/2006 | CA2599953A1 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| 09/08/2006 | CA2599875A1 Preventive/therapeutic agent for cancer |
| 09/08/2006 | CA2599867A1 Antiallergic composition |
| 09/08/2006 | CA2599861A1 Production process for nsaid-containing lozenges, their compositions, their medicinal use |
| 09/08/2006 | CA2599848A1 1,2,4-triazine derivatives, preparation and use thereof in human therapy |
| 09/08/2006 | CA2599843A1 Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| 09/08/2006 | CA2599808A1 2- [ isoquinolin-s - carbonyl ) amino] -propionic acid derivatives as inhibitors of factors xi and ix for the treatment of thrombosis |
| 09/08/2006 | CA2599718A1 Methods and pharmaceutical compositions for the treatment of neurological damage |
| 09/08/2006 | CA2599712A1 Folic acid-, vitamin b6- and vitamin b12-containing agents and the use thereof |
| 09/08/2006 | CA2599688A1 Cinnoline compounds and their use as liver x receptor modulators |
| 09/08/2006 | CA2599662A1 Use of pde7 inhibitors for the treatment of neuropathic pain |
| 09/08/2006 | CA2599658A1 Diosmetin derivatives for the treatment and prevention of thrombotic pathologies |
| 09/08/2006 | CA2599612A1 Use of phosphate derivatives of electron transfer agents for lowering increased circulating blood levels of a lipid |
| 09/08/2006 | CA2599588A1 Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
| 09/08/2006 | CA2599582A1 Purification of rapamycin |
| 09/08/2006 | CA2599544A1 Novel aminopyridine compound with syk inhibitory activity |
| 09/08/2006 | CA2599424A1 Compounds having anti-cancer properties |
| 09/08/2006 | CA2599404A1 Quinolinone compounds as 5-ht4 receptor agonists |
| 09/08/2006 | CA2599379A1 Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy |
| 09/08/2006 | CA2599352A1 Novel lipoxygenase inhibitors |
| 09/08/2006 | CA2599331A1 Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals preparation comprising the same |
| 09/08/2006 | CA2599312A1 Process for the production of calcium compositions in a continuous fluid bed |
| 09/08/2006 | CA2599270A1 Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, preparation method, compositions containing same and use |
| 09/08/2006 | CA2599205A1 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
| 09/08/2006 | CA2599196A1 Pharmaceutical composition comprising an indolylmaleimide derivative |
| 09/08/2006 | CA2599165A1 Derivatives of aminobutanoic acid inhibiting cpt |
| 09/08/2006 | CA2599017A1 Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| 09/08/2006 | CA2598860A1 Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives |
| 09/08/2006 | CA2598858A1 6 -heteroaryl-1, 2, 3,4,4a, 1ob-hexahydro-phenanthridines as pde-4 inhibitors for the treatment of inflammatory disorders |
| 09/08/2006 | CA2598785A1 Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids |
| 09/08/2006 | CA2598668A1 Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents |
| 09/08/2006 | CA2598647A1 Tetracyclic amino and carboxamido compounds and methods of use thereof |
| 09/08/2006 | CA2598598A1 Antifungal compositions comprising sertaconazol and hydrocortisone and/or an antibacterial quinolone compound |
| 09/08/2006 | CA2598331A1 Amide derivatives of hyaluronic acid in osteoarthrosis |
| 09/08/2006 | CA2597685A1 Tricyclic-nucleoside compounds for treating viral infections |
| 09/08/2006 | CA2597683A1 Tricyclic-nucleoside prodrugs for treating viral infections |
| 09/08/2006 | CA2597576A1 Isoquinoline compounds and methods of use thereof |
| 09/08/2006 | CA2597463A1 Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use |
| 09/08/2006 | CA2597155A1 Room temperature stable aqueous liquid pharmaceutical composition |
| 09/08/2006 | CA2596867A1 Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin |
| 09/08/2006 | CA2574088A1 Oligonucleotides comprising a modified or non-natural nucleobase |
| 09/07/2006 | WO2006078903B1 Radiosensitizer formulations comprising nitrohistidine derivatives |
| 09/07/2006 | US20060200213 Method and apparatus for skin treatment |
| 09/07/2006 | US20060199978 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders |
| 09/07/2006 | US20060199957 Novel bicyclic and tricyclic cannabinoids |
| 09/07/2006 | US20060199956 Bicyclic heterocycles as HIV integrase inhibitors |
| 09/07/2006 | US20060199954 non-yellow color, purity antibiotics; reacting with chlorotrimethylsilane to yield 31,42-bis-trimethylsilyl ether, heptane solvent extraction, and de-protection with sulfuric acid |
| 09/07/2006 | US20060199869 Reducing digestion of lipids to treat or prevent obesity by administering an acyclic amine optionally containing ether groups or a sulfide group, e.g., 2-(Dimethylamino)ethyl stearyl ether, N,N-dimethylhexadecylamine, or 2-(Diisopropylamino)ethyl dodecyl ether |
| 09/07/2006 | US20060199868 Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina |